Enzo Biochem, Inc. (NYSE:ENZ) CFO Sells $85,250.00 in Stock

Enzo Biochem, Inc. (NYSE:ENZ) CFO Barry W. Weiner sold 11,000 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the transaction, the chief financial officer now directly owns 1,313,111 shares in the company, valued at approximately $10,176,610.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Enzo Biochem, Inc. (NYSE:ENZ) traded down $0.12 during midday trading on Monday, hitting $6.73. The stock had a trading volume of 106,128 shares, compared to its average volume of 194,508. The firm has a market capitalization of $315.81, a price-to-earnings ratio of -168.25 and a beta of 0.70. Enzo Biochem, Inc. has a 52 week low of $6.36 and a 52 week high of $12.04.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.01). The company had revenue of $27.68 million for the quarter, compared to analyst estimates of $27.51 million. Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%.

A number of institutional investors have recently made changes to their positions in ENZ. Evermore Global Advisors LLC raised its position in Enzo Biochem by 23.8% in the 4th quarter. Evermore Global Advisors LLC now owns 4,562,775 shares of the medical research company’s stock valued at $37,187,000 after buying an additional 877,255 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Enzo Biochem by 10.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,026,647 shares of the medical research company’s stock valued at $22,376,000 after buying an additional 193,246 shares during the last quarter. TIAA CREF Investment Management LLC raised its position in Enzo Biochem by 43.9% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 533,923 shares of the medical research company’s stock valued at $5,895,000 after buying an additional 162,854 shares during the last quarter. ClariVest Asset Management LLC raised its position in Enzo Biochem by 55.8% in the 3rd quarter. ClariVest Asset Management LLC now owns 414,898 shares of the medical research company’s stock valued at $4,344,000 after buying an additional 148,578 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware raised its position in Enzo Biochem by 39.8% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 455,042 shares of the medical research company’s stock valued at $5,024,000 after buying an additional 129,538 shares during the last quarter. 65.38% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/12/barry-w-weiner-sells-11000-shares-of-enzo-biochem-inc-enz-stock.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply